Does routine CYP2D6 and CYP2C19 genotyping reduce the risk of adverse events related to antipsychotic drug treatment?

Gesche Jürgens; Stig Ejdrup Andersen; Heidi Jensen; Henrik Berg Rasmussen; Thomas Mears Werge; Merete Nordentoft

Does routine CYP2D6 and CYP2C19 genotyping reduce the risk of adverse events related to antipsychotic drug treatment?

Gesche Jürgens, Stig Ejdrup Andersen, Heidi Jensen, Henrik Berg Rasmussen, Thomas Mears Werge, Merete Nordentoft

Original language	English
Journal	Clinical Toxicology
Volume	51
Issue number	4
Pages (from-to)	325-325
Number of pages	1
ISSN	1556-3650
Publication status	Published - 2013

Cite this

@article{05acfd8dff884ba4bd398eab9fe3c384,

title = "Does routine CYP2D6 and CYP2C19 genotyping reduce the risk of adverse events related to antipsychotic drug treatment?",

author = "Gesche J{\"u}rgens and Andersen, \{Stig Ejdrup\} and Heidi Jensen and Rasmussen, \{Henrik Berg\} and Werge, \{Thomas Mears\} and Merete Nordentoft",

year = "2013",

language = "English",

volume = "51",

pages = "325--325",

journal = "Clinical Toxicology",

issn = "1556-3650",